Cargando…
Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Background: This study aimed to analyze the cost effectiveness of camrelizumab in the second-line treatment of advanced or metastatic esophageal squamous cell carcinoma in China. Methods: On the basis of the ESCORT clinical trial, a partitioned survival model was constructed to simulate the patient’...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8634950/ https://www.ncbi.nlm.nih.gov/pubmed/34867339 http://dx.doi.org/10.3389/fphar.2021.732912 |
_version_ | 1784608212669956096 |
---|---|
author | Cai, Hongfu Xu, Baohua Li, Na Zheng, Bin Zheng, Zhiwei Liu, Maobai |
author_facet | Cai, Hongfu Xu, Baohua Li, Na Zheng, Bin Zheng, Zhiwei Liu, Maobai |
author_sort | Cai, Hongfu |
collection | PubMed |
description | Background: This study aimed to analyze the cost effectiveness of camrelizumab in the second-line treatment of advanced or metastatic esophageal squamous cell carcinoma in China. Methods: On the basis of the ESCORT clinical trial, a partitioned survival model was constructed to simulate the patient’s lifetime quality-adjusted life years (QALYs), lifetime costs, and incremental cost-effectiveness ratio (ICER). One-way sensitivity and probability sensitivity analyses were performed to test the stability of the model. Results: Treatment of esophageal squamous cell carcinoma with camrelizumab added 0.36 QALYs and resulted in an incremental cost of $1,439.64 compared with chemotherapy, which had an ICER of $3,999 per QALY gained. The ICER was far lower than the threshold of willingness to pay for one time the GDP per capita in China. Sensitivity analysis revealed that the ICERs were most sensitive to the cost of drugs, but the parameters did not have a major effect on the results of the model. Conclusion: Camrelizumab is likely to be a cost-effective option compared with chemotherapy for patients with advanced or metastatic esophageal squamous cell carcinoma. This informs patient selection and clinical path development. |
format | Online Article Text |
id | pubmed-8634950 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86349502021-12-02 Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma Cai, Hongfu Xu, Baohua Li, Na Zheng, Bin Zheng, Zhiwei Liu, Maobai Front Pharmacol Pharmacology Background: This study aimed to analyze the cost effectiveness of camrelizumab in the second-line treatment of advanced or metastatic esophageal squamous cell carcinoma in China. Methods: On the basis of the ESCORT clinical trial, a partitioned survival model was constructed to simulate the patient’s lifetime quality-adjusted life years (QALYs), lifetime costs, and incremental cost-effectiveness ratio (ICER). One-way sensitivity and probability sensitivity analyses were performed to test the stability of the model. Results: Treatment of esophageal squamous cell carcinoma with camrelizumab added 0.36 QALYs and resulted in an incremental cost of $1,439.64 compared with chemotherapy, which had an ICER of $3,999 per QALY gained. The ICER was far lower than the threshold of willingness to pay for one time the GDP per capita in China. Sensitivity analysis revealed that the ICERs were most sensitive to the cost of drugs, but the parameters did not have a major effect on the results of the model. Conclusion: Camrelizumab is likely to be a cost-effective option compared with chemotherapy for patients with advanced or metastatic esophageal squamous cell carcinoma. This informs patient selection and clinical path development. Frontiers Media S.A. 2021-11-16 /pmc/articles/PMC8634950/ /pubmed/34867339 http://dx.doi.org/10.3389/fphar.2021.732912 Text en Copyright © 2021 Cai, Xu, Li, Zheng, Zheng and Liu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Cai, Hongfu Xu, Baohua Li, Na Zheng, Bin Zheng, Zhiwei Liu, Maobai Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma |
title | Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma |
title_full | Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma |
title_fullStr | Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma |
title_full_unstemmed | Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma |
title_short | Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma |
title_sort | cost-effectiveness analysis of camrelizumab versus chemotherapy as second-line treatment of advanced or metastatic esophageal squamous cell carcinoma |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8634950/ https://www.ncbi.nlm.nih.gov/pubmed/34867339 http://dx.doi.org/10.3389/fphar.2021.732912 |
work_keys_str_mv | AT caihongfu costeffectivenessanalysisofcamrelizumabversuschemotherapyassecondlinetreatmentofadvancedormetastaticesophagealsquamouscellcarcinoma AT xubaohua costeffectivenessanalysisofcamrelizumabversuschemotherapyassecondlinetreatmentofadvancedormetastaticesophagealsquamouscellcarcinoma AT lina costeffectivenessanalysisofcamrelizumabversuschemotherapyassecondlinetreatmentofadvancedormetastaticesophagealsquamouscellcarcinoma AT zhengbin costeffectivenessanalysisofcamrelizumabversuschemotherapyassecondlinetreatmentofadvancedormetastaticesophagealsquamouscellcarcinoma AT zhengzhiwei costeffectivenessanalysisofcamrelizumabversuschemotherapyassecondlinetreatmentofadvancedormetastaticesophagealsquamouscellcarcinoma AT liumaobai costeffectivenessanalysisofcamrelizumabversuschemotherapyassecondlinetreatmentofadvancedormetastaticesophagealsquamouscellcarcinoma |